Worth reading
90Important
Scored from 2 of 5 sectionsDirection
Neutral
Direction inferred from the company’s description.Scale
775
¥ million (total use of proceeds; no change in amount)Wording
Conditional
How definitive the wording is.Details of issuance or disposal
Specific use of funds
Acquisition of a columbarium-related businessAmount ¥250 million / Scheduled timing of expenditures May 2026 to June 2026
Acquisition of shares in a funeral company through M&AAmount ¥185 million / Scheduled timing of expenditures May 2026 to January 2027
Acquisition of shares in a stonework contractor through M&AAmount ¥80 million / Scheduled timing of expenditures December 2026
Acquisition of shares in an insurance agency through M&AAmount ¥150 million / Scheduled timing of expenditures June 2026 to July 2027
Acquisition of shares in a funeral company through M&AAmount ¥100 million / Scheduled timing of expenditures July 2026 to September 2027
Capital and business alliance related to DX to support collaboration with the end-of-life planning businessAmount ¥10 million / Scheduled timing of expenditures February 2027
Most recent equity financing
This financing through the shares, bonds with stock acquisition rights and stock acquisition rights disclosed on 16 April 2026. However, this document does not provide details of the amount.
Impact on Business Performance
The impact of this matter on the results for the current fiscal year is currently being assessed. If any matter requiring disclosure arises, the company will notify investors promptly.
| Item | Details |
|---|---|
| Specific use of funds | Details Acquisition of a columbarium-related business / Amount ¥250 million / Scheduled timing of expenditures May 2026 to June 2026, Details Acquisition of shares in a funeral company through M&A / Amount ¥185 million / Scheduled timing of expenditures May 2026 to January 2027, Details Acquisition of shares in a stonework contractor through M&A / Amount ¥80 million / Scheduled timing of expenditures December 2026, Details Acquisition of shares in an insurance agency through M&A / Amount ¥150 million / Scheduled timing of expenditures June 2026 to July 2027, Details Acquisition of shares in a funeral company through M&A / Amount ¥100 million / Scheduled timing of expenditures July 2026 to September 2027, Details Capital and business alliance related to DX to support collaboration with the end-of-life planning business / Amount ¥10 million / Scheduled timing of expenditures February 2027 |
| Most recent equity financing | This financing through the shares, bonds with stock acquisition rights and stock acquisition rights disclosed on 16 April 2026. However, this document does not provide details of the amount. |
| Impact on Business Performance | The impact of this matter on the results for the current fiscal year is currently being assessed. If any matter requiring disclosure arises, the company will notify investors promptly. |
Items this document does not state (25)
Type of issuance or disposalNumber of shares to be issued or disposed ofIssue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesPayment dateIntended allotteeIntended allottee's holding policyDilution RateTotal number of issued sharesBasis for determining the amount to be paidExercise priceExercise periodNumber of Stock Acquisition RightsTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioProcedures under the Corporate Code of ConductMajor shareholders after the offering
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Negotiations with the target companies regarding acquisition prices and other terms, as well as detailed coordination toward executing the agreements, have taken longer than expected, and discussions are continuing to finalize the optimal contractual terms. The expenditure timing for counterparties with which negotiations will newly commence may also be delayed.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.